OakChart

Precision Biosciences Inc

DTILHealthcare·Biotechnology·USA·Micro·NASD·Nov 11 • 11:27 AM ET

9.21-0.29 (-3.05%)
2026-11-11 17:28 CET
Market cap
265.39 USD m
Revenue, TTM
45.04 USD m
Net income, TTM
-39.43 USD m
Free cash flow, TTM
-47.76 USD m
EPS diluted, TTM
-1.28
P/E
-
Compare

Price

DTIL against its 20, 50 and 200-day averages
2050200beatmiss
6.008.0010.001.7M3.3MMay 26Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26DTILclose 9.2120-day 7.5450-day 7.00200-day 6.739.2152w high

18.4% under the 52-week high of 11.29 on 5 Nov 2026. 52-week low 3.53 on 5 Feb 2026. Last 15 sessions, 79.5% high to low

Profile

DTIL
52-week range, 73% of the way up
3.5311.29

Precision BioSciences, Inc. is a biotechnology company, which engages in the development of genome editing technologies. It operates through the Therapeutics and Food segments. The Therapeutics segment focuses on the development of products in the field of immuno-oncology and of novel products outside immuno-oncology to treat human diseases. The Food segment applies ARCUS, the company's proprietary genome editing platform, to develop food and nutrition products through collaboration agreements with consumer-facing companies. The company was founded by Derek N. Jantz, Jeff Smith, and Matthew R. Kane on January 26, 2006 and is headquartered in Durham, NC.

IndexRUT
Employees68
IPOMar 28, 2019
Beta1.29
ATR, 14d0.79
Rel volume1.01
Short float8.68%
Insider own13.49%
Inst own59.15%

Snapshot

6 groups

Valuation

IndexRUT
Market Cap257.29M
Enterprise Value203.16M
Income-39.43M
Sales45.04M
Book/sh1.86
Cash/sh2.93
Dividend Est.-
Dividend TTM-
Dividend Ex-Date-
Dividend Gr. 3/5Y- -
Payout-
Employees68
IPOMar 28, 2019

Ratios

P/E-
Forward P/E-
PEG-
P/S5.71
P/B4.96
P/C3.14
P/FCF-
EV/EBITDA-
EV/Sales4.51
Quick Ratio10.47
Current Ratio10.47
Debt/Eq0.54
LT Debt/Eq0.50
Option/ShortYes / Yes

Earnings

EPS (ttm)-1.28
EPS next Y-2.19
EPS next Q-0.68
EPS this Y20.62%
EPS next Y22.43%
EPS next 5Y20.78%
EPS past 3/5Y54.31% 43.45%
Sales past 3/5Y10.93% 7.13%
EPS Y/Y TTM84.80%
Sales Y/Y TTM6353.01%
EPS Q/Q84.99%
Sales Q/Q-100.00%
EarningsNov 03 BMO
EPS/Sales Surpr.67.06% -100.00%

Ownership

Insider Own13.49%
Insider Trans0.13%
Inst Own59.15%
Inst Trans0.46%
ROA-36.87%
ROE-115.28%
ROIC-50.66%
Gross Margin94.45%
Oper. Margin-80.27%
Profit Margin-87.54%
SMA2022.08%
SMA5031.51%
SMA20036.87%
Trades-

Technical

Shs Outstand27.89M
Shs Float24.17M
Short Float8.68%
Short Ratio6.65
Short Interest2.10M
52W High11.29 -18.42%
52W Low3.53 160.91%
Volatility17.65% 9.84%
ATR (14)0.79
RSI (14)63.60
Beta1.29
Rel Volume1.01
Avg Volume315.49K
Volume107,276

Performance

Perf Week13.42%
Perf Month50.98%
Perf Quarter26.16%
Perf Half Y10.43%
Perf YTD121.39%
Perf Year53.50%
Perf 3Y-18.95%
Perf 5Y-97.00%
Perf 10Y-
Recom1.00
Target Price29.40
Prev Close9.50
Price9.21
Change %-3.05%

Analyst ratings

latest 10 of 15
DateActionAnalystRating changeTargetImplied
Jun 09, 2026InitiatedOOppenheimerOutperform$20+117.2%
Jan 10, 2025UpgradeBBMO Capital MarketsMarket Perform → Outperform$34+269.2%
Apr 30, 2024InitiatedGGuggenheimBuy$19+106.3%
Jun 17, 2022InitiatedBBMO Capital MarketsOutperform$7-24.0%
Jun 09, 2022DowngradeWWilliam BlairOutperform → Mkt Perform
Jul 27, 2020ResumedBBTIG ResearchBuy$16+73.7%
Apr 03, 2020DowngradeGGoldmanBuy → Neutral$24 → $7-24.0%
Mar 05, 2020InitiatedSStifelBuy$21+128.0%
Feb 25, 2020InitiatedWWilliam BlairOutperform
Aug 09, 2019InitiatedBBTIG ResearchBuy$22+138.9%

Peers

Mkt cap
TickerCompanyMkt cap
EDITEditas Medicine Inc383.53M
PRMEPrime Medicine Inc782.64M
ABUSArbutus Biopharma Corp761.71M
NTLAIntellia Therapeutics Inc1.61B
SCTXScribe Therapeutics Inc335.65M
BEAMBeam Therapeutics Inc2.63B
CRBUCaribou Biosciences Inc41.07M
ALGSAligos Therapeutics Inc16.91M
SLDBSolid Biosciences Inc867.64M
VIRVir Biotechnology Inc2.25B

Insider trading

latest 14 of 30
InsiderRelationshipDateTransactionCostSharesValueTotal heldForm
Scimeca DarioOfficerNov 10 '26Proposed Sale9.752,82127,517Nov 10 10:50 AM
SMITH J. JEFFERSONOfficerNov 06 '26Proposed Sale10.248758,956Nov 06 04:30 PM
SMITH J. JEFFERSONOfficerNov 05 '26Proposed Sale10.267,05672,412Nov 05 04:15 PM
Frankel StanleyDirectorSep 28 '26Buy6.001,0006,00041,478Sep 30 04:15 PM
Brown MelindaDirectorSep 25 '26Buy6.271,1357,11645,481Sep 29 07:00 AM
Germano Geno JDirectorSep 25 '26Buy6.282,60916,38547,492Sep 29 07:00 AM
Amoroso MichaelPresident and CEOFeb 17 '26Option Exercise0.0067,7970263,951Feb 19 04:31 PM
Amoroso MichaelPresident and CEOFeb 18 '26Sale3.8420,55978,947243,392Feb 19 04:31 PM
Kelly John AlexanderChief Financial OfficerFeb 17 '26Option Exercise0.0027,5840134,032Feb 19 04:31 PM
Kelly John AlexanderChief Financial OfficerFeb 18 '26Sale3.848,14931,292125,883Feb 19 04:31 PM
Scimeca DarioGeneral Counsel and SecretaryFeb 17 '26Option Exercise0.0016,667061,382Feb 19 04:30 PM
Scimeca DarioGeneral Counsel and SecretaryFeb 18 '26Sale3.844,92518,91256,457Feb 19 04:30 PM
SMITH J. JEFFERSONChief Research OfficerFeb 17 '26Option Exercise0.0016,6670126,851Feb 19 04:30 PM
SMITH J. JEFFERSONChief Research OfficerFeb 18 '26Sale3.844,92518,912121,926Feb 19 04:30 PM

Held by

AUM
TickerCompanyAUM
IWMiShares Russell 2000 Index FundAUM: 77.38B
VTIVanguard Morningstar Total Stock Market ETFAUM: 687.42B
IWNiShares Russell 2000 Value ETFAUM: 14.10B
VXFVanguard Extended Market Index ETFAUM: 30.47B
FESMFidelity Enhanced Small Cap Core ETFAUM: 6.82B
VTWOVanguard Russell 2000 Index ETFAUM: 16.75B
IWCiShares Micro-Cap ETFAUM: 1.22B
DFASU.S. Small Cap Portfolio-ETF Class Shares-
AVSCAvantis U.S Small Cap Equity ETFAUM: 3.23B
GSSCGoldman Sachs ActiveBeta U.S. Small Cap Equity ETFAUM: 1.06B

News

latest 14 of 206
  • Precision BioSciences Announces Late-Breaking PBGENE-HBV Data at AASLD The Liver Meeting 2026 Further Demonstrating cccDNA Elimination and Potential to Drive Viral Cure (Business Wire) +21.55%
  • Precision BioSciences Announces Pricing of $125 Million Underwritten Offering of Common Stock and Pre-Funded Warrants (Business Wire)
  • Precision BioSciences Announces Positive DSMB Safety Review Supporting Additional PBGENE-DMD Dosing in Phase 1/2 FUNCTION-DMD Study (Business Wire)
  • Precision BioSciences: Q3 Earnings Snapshot (Associated Press)
  • Precision BioSciences Reports Third Quarter 2026 Financial Results and Provides Business Update (Business Wire)
  • Loading…
  • Precision BioSciences Faces A Wider Expected Loss As Bearish Sentiment Builds Ahead Of Q3 (Earnings Whispers)
  • Precision BioSciences to Report Third Quarter 2026 Financial Results on November 3, 2026 (Business Wire)
  • Precision BioSciences Announces Late-Breaking Oral Presentation for PBGENE-HBV at AASLD The Liver Meeting 2026 (Business Wire)
  • Precision BioSciences Commences Dosing in Phase 1/2 FUNCTION-DMD Study (Business Wire)
  • Precision BioSciences: Q2 Earnings Snapshot (Associated Press)
  • Precision BioSciences Reports Second Quarter 2026 Financial Results and Provides Business Update (Business Wire)
  • Precision BioSciences to Report Second Quarter 2026 Financial Results on August 6, 2026 (Business Wire)
  • Precision BioSciences Announces Changes to Senior Leadership Team to Support Advancement of Programs Through Next Set of Clinical Milestones (Business Wire)

Quarterly earnings

actual against estimate
PeriodReportedEPS actEPS estEPS repSales actSales estAnalysts
2026Q32026-11-03-0.280-0.850-0.3300.001.385
2026Q22026-08-06-1.260-0.804-1.2630.000.745
2026Q12026-05-05-0.750-0.655-0.74910.844.054
2025Q42026-03-121.050-0.5351.00434.209.084
2025Q32025-11-03-1.840-1.340-1.8420.015.403
2025Q22025-08-07-2.130-1.500-2.1290.024.983
2025Q12025-05-15-2.210-1.958-2.2130.034.064
2024Q42025-03-26-2.220-2.253-2.2180.644.264
2024Q32024-11-04-2.250-2.136-2.2540.585.345
2024Q22024-08-014.670-2.1224.67149.907.706
2024Q12024-05-131.700-2.3691.69617.585.347
2023Q42024-03-27-4.060-2.048-4.0627.0412.474
2023Q32023-11-07-2.100-5.475-4.30413.128.994
2023Q22023-08-04-3.000-7.320-3.12719.796.385
2023Q12023-05-09-6.900-6.780-6.7558.805.685
2022Q42023-03-09-7.800-6.075-7.70310.606.819

Annual earnings

PeriodEPS actEPS estEPS repSales actSales est
2019FY-66.300-67.725-66.35522.2422.71
2020FY-62.700-65.486-62.85024.2921.26
2021FY-15.600-18.838-15.643115.53116.73
2022FY-38.100-35.727-38.10325.1021.58
2023FY-15.960-15.090-18.16148.7353.27
2024FY1.0400.0681.04168.7072.30
2025FY-3.560-6.135-3.56034.269.14
2026FY--2.826--11.35
2027FY--2.192--8.74
2028FY--1.770--17.58
2029FY--1.808--23.78
2030FY--0.263--142.99

Estimate revisions

last 14 periods
PeriodTypeDateEstimatesUpDownMeanLowHigh
2026Q4S2026-11-045001.000.002.50
2026Q4S2026-11-034001.250.002.50
2026Q4S2026-10-144001.250.002.50
2026Q4S2026-09-164011.250.002.50
2026Q4S2026-08-065011.000.002.50
2026Q4S2026-07-315011.000.002.50
2026Q4S2026-07-195004.540.0017.70
2026Q4S2026-06-085104.540.0017.70
2026Q4S2026-05-054105.680.0017.70
2026Q4S2026-03-184015.480.0016.90
2026Q4S2026-03-173001.670.002.50
2026Q4S2026-03-122002.502.502.50
2026Q4S2026-01-1710018.7018.7018.70
2026Q4S2025-11-1110118.7018.7018.70

Estimate history

EPS, annual-12.607-27.505-66.355-62.85-15.643-38.103-18.1611.041-3.634-1.2839
Period201720182019202020212022202320242025TTM
EPS, quarterly-2.254-2.218-2.213-2.129-1.8421.004-0.749-1.263-0.277
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Sales, annual6.48410.88322.23824.285115.52925.09848.72768.69634.26445.04
Period201720182019202020212022202320242025TTM
Sales, quarterly0.5760.6380.0290.0180.01334.20410.83800
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Shares, annual1.6741.6741.7051.7562.033.6994.1648.20324.08827.893
Period201720182019202020212022202320242025MRQ
Shares, quarterly7.4818.20310.54911.63712.08324.08825.80626.43427.893
PeriodQ3 '24Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26

Income statement, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Total Revenue45.0434.2668.7048.7325.10115.5324.2922.2410.88
Cost of Goods Sold Incl. D&A2.502.754.588.269.00----
Gross Profit42.5431.5164.1240.4716.09----
Selling, General and Administrative Excl. Other78.7083.6690.2884.2178.40144.73124.30104.1256.44
Research and Development51.6952.8756.8449.3542.11107.6690.6278.2343.36
Other Operating Expense0.000.000.000.000.000.000.000.000.00
Operating Income-36.16-52.15-26.16-43.74-62.31-39.40-109.83-87.20-47.91
Interest Expense1.271.421.782.231.110.130.000.180.00
Unusual Expense-0.15-8.43-29.87-1.1511.35-8.540.009.760.00
Net Income Before Taxes-39.43-46.617.17-42.53-72.91-30.60-109.01-92.88-46.04
Income Taxes0.000.000.000.000.000.000.000.000.00
Consolidated Net Income-39.43-46.617.17-42.53-72.91-30.60-109.01-92.88-46.04
Net Income From Continuing Operations-39.43-46.617.17-42.53-72.91-30.60-109.01-92.88-46.04
Net Income-39.43-46.617.17-69.77-111.64-30.60-109.01-92.88-46.04
EPS (Recurring)-1.44-4.09-2.00-18.37-35.39-18.70-62.85-61.47-27.50
EPS (Basic, Before Extraordinaries)-1.28-3.631.05-18.16-38.10-15.64-62.85-66.35-27.50
EPS (Diluted)-1.28-3.631.04-18.16-38.10-15.64-62.85-66.35-27.50
EBITDA-33.66-49.40-21.59-35.48-53.30-29.20-100.02-81.89-45.56
Non-Operating Income (Expense)3.21-1.475.242.291.860.390.824.271.88
Other After Tax Adjustments0.000.000.000.000.000.000.000.000.00
Stock Option Compensation Expense7.969.5111.0212.3615.9214.9612.648.352.45
Price To Earnings Ratio--74.56------
Price To Sales Ratio3.811.560.380.864.173.7617.8726.23-
Gross Margin94.4591.9793.3483.0664.12----
Operating Margin-80.27-152.19-38.08-89.76-248.26-34.11-452.25-392.14-440.25
Net Margin-87.54-136.0310.43-143.18-444.80-26.49-448.86-417.65-423.02
Shares Outstanding27.8924.098.204.163.702.031.761.711.67
Market Capitalization265.39265.3915.4842.22132.01450.68439.46710.55684.92

Income statement, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q22025Q12024Q4
Total Revenue0.000.0010.8434.200.010.020.030.64
Cost of Goods Sold Incl. D&A0.580.600.640.680.670.700.700.76
Gross Profit-0.58-0.6010.2033.53-0.66-0.68-0.68-0.12
Selling, General and Administrative Excl. Other19.8518.5619.2721.0220.0121.2021.4424.73
Research and Development12.5412.1612.8314.1413.0412.4413.2515.51
Other Operating Expense0.000.000.000.000.000.000.000.00
Operating Income-20.43-19.16-9.0712.51-20.67-21.88-22.11-24.85
Interest Expense0.310.300.310.350.360.360.350.39
Unusual Expense-12.2714.1310.06-12.071.181.710.76-7.15
Net Income Before Taxes-7.59-32.65-18.4419.25-21.77-23.52-20.57-17.75
Income Taxes0.000.000.000.000.000.000.000.00
Consolidated Net Income-7.59-32.65-18.4419.25-21.77-23.52-20.57-17.75
Net Income From Continuing Operations-7.59-32.65-18.4419.25-21.77-23.52-20.57-17.75
Net Income-7.59-32.65-18.4419.25-21.77-23.52-20.57-17.75
EPS (Recurring)-0.59-0.88-0.460.56-1.77-2.02-2.16-2.84
EPS (Basic, Before Extraordinaries)-0.28-1.26-0.751.01-1.84-2.13-2.21-2.22
EPS (Diluted)-0.28-1.26-0.751.00-1.84-2.13-2.21-2.22
EBITDA-19.85-18.56-8.4413.19-19.99-21.18-21.41-24.09
Non-Operating Income (Expense)0.880.941.00-4.990.440.432.660.34
Other After Tax Adjustments0.000.000.000.000.000.000.000.00
Stock Option Compensation Expense2.961.691.411.902.232.742.643.22
Price To Earnings Ratio------2.5274.56
Price To Sales Ratio3.814.513.012.3393.4636.790.870.44
Gross Margin--94.0998.02-5,084.62-3,766.67-2,331.03-18.65
Operating Margin---83.7336.57-158,976.92-121,538.89-76,248.28-3,894.36
Net Margin---170.1556.27-167,476.92-130,666.67-70,913.79-2,781.35
Shares Outstanding27.8926.4325.8124.0912.0811.6410.558.20
Market Capitalization265.39202.81136.00100.1465.0646.5719.3915.48

Balance sheet, annual

Currency USD, millions
Metric2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY
Cash & Short Term Investments115.5886.31116.68189.58143.6689.80180.89103.1962.80
Short Term Receivables0.001.7012.800.720.4910.000.961.030.02
Inventories0.000.000.000.000.000.000.000.000.00
Other Current Assets3.156.986.888.8117.605.7711.828.911.44
Total Current Assets118.7494.99136.36199.10161.75105.56193.67113.1364.26
Net Property, Plant & Equipment7.2310.1814.6013.7829.3341.5039.5721.158.14
Total Investments and Advances27.0725.773.214.756.840.000.000.000.00
Long-Term Note Receivable0.004.604.997.236.88----
Intangible Assets1.170.620.400.732.051.371.431.470.09
Other Assets0.210.220.2312.574.641.720.562.850.19
Total Assets154.42136.39159.78238.17211.50150.16235.23138.6072.68
Short Term Debt Incl. Current Port. of LT Debt1.511.3223.551.681.821.930.000.000.00
Accounts Payable0.301.312.970.651.140.792.042.221.81
Other Current Liabilities7.1112.3523.4757.3333.0140.1024.8911.867.40
Total Current Liabilities8.9114.9849.9959.6635.9842.8326.9314.079.20
Long Term Debt27.3028.737.7223.287.298.590.000.000.00
Provision for Risks Charges0.000.000.000.000.000.000.000.000.00
Other Liabilities25.9536.2983.2194.7977.0654.3269.9984.5689.85
Total Liabilities62.1780.00140.92177.74120.33105.7396.9298.6499.05
Non-Equity Reserves0.000.000.000.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.000.000.010.00
Common Equity92.2556.3918.8660.4391.1744.42138.3139.95-26.37
Total Shareholders Equity92.2556.3918.8660.4391.1744.42138.3139.96-26.37
Accumulated Minority Interest0.000.000.000.000.000.000.000.000.00
Total Equity92.2556.3918.8660.4391.1744.42138.3139.96-26.37
Total Liabilities & Stockholders Equity154.42136.39159.78238.17211.50150.16235.23138.6072.68
Book Value Per Share3.836.874.5316.3444.9125.2981.1123.87-15.76
Tangible Book Value Per Share3.786.804.4316.1443.9024.5180.2722.99-15.81
Full-Time Employees68108109198198231199127-
Price to Book Ratio5.120.441.451.564.949.895.144.40-
Return on Assets-32.064.84-21.37-32.43-16.92-56.57-49.69-43.58-24.67
Return on Equity-62.7119.05-107.26-96.19-45.14-119.30-104.20-677.46-
Return on Invested Capital-38.998.42-262.43-133.35-31.08-205.63-67.15-115.21-
Quick Ratio13.326.342.733.344.502.467.198.046.98
Current Ratio13.326.342.733.344.502.467.198.046.98

Cash flow, annual

Currency USD, millions
MetricTTM2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY
Net Income-38.55-45.727.17-61.32-111.64-30.60-109.01-92.88-46.04
Depreciation2.502.754.588.269.0010.209.815.322.35
Other Funds (Non Cash)13.696.37-16.1910.4432.77-10.0413.8216.280.33
Funds from Operations-22.35-36.60-4.45-42.63-69.86-30.45-85.37-71.28-43.35
Extraordinary Item0.000.000.000.000.000.000.000.000.00
Changes in Working Capital-25.37-24.71-55.99-41.4924.1119.58-2.01-2.36-10.51
Cash from Operating Activities-47.72-61.31-60.44-84.11-45.75-10.87-87.39-73.64-53.86
Capital Expenditures-0.69-0.70-0.28-2.28-3.32-5.80-5.03-24.67-15.68
Net Assets From Acquisitions0.000.000.000.000.000.000.000.00-
Sale of Fixed Assets and Businesses0.050.070.068.110.000.000.000.000.01
Purchase or Sale of Investments0.000.000.000.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.000.000.00-
Cash from Investing Activities-0.64-0.63-0.215.83-3.32-5.80-5.03-24.67-15.66
Cash Dividends Paid0.000.000.000.000.000.000.000.000.00
Change in Capital Stock89.2295.1650.495.3975.1868.061.33136.450.17
Repurchase of Common Pref Stock0.000.000.000.000.000.000.000.000.00
Sale of Common Pref Stock89.2295.1650.495.3975.1868.061.33136.450.17
Proceedsfrom Stock Options19.0224.960.915.3674.7961.280.64135.190.00
Issuance or Reduction of Debt, Net0.000.00-0.040.0019.802.470.0039.550.00
Change in Long Term Debt0.000.00-0.040.0019.802.470.000.000.00
Issuance of Long Term Debt0.000.0022.470.0019.804.970.000.000.00
Reduction of Long Term Debt0.000.00-22.500.000.00-2.500.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.000.000.00109.74
Other Financing Activities Uses0.000.000.000.000.000.000.000.000.00
Cash from Financing Activities89.2295.1650.455.3994.9870.531.33176.00109.91
Net Change in Cash40.8633.22-10.20-72.9045.9153.87-91.0977.69-
Free Cash Flow-47.76-61.39-60.69-86.07-49.07-15.92-92.42-98.30-68.14
Preferred Dividends (Cash Flow)-0.000.000.000.000.000.000.00-
Deferred Taxes & Investment Tax Credit-0.000.000.000.000.000.000.000.00

Balance sheet, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Cash & Short Term Investments81.8587.55101.18115.5844.8762.24
Short Term Receivables0.000.004.000.000.000.00
Inventories0.000.000.000.000.000.00
Other Current Assets4.734.003.513.156.838.02
Total Current Assets86.5891.55108.69118.7451.7070.26
Net Property, Plant & Equipment5.546.086.657.238.168.82
Total Investments and Advances27.0827.0727.2227.0727.0923.31
Intangible Assets1.061.091.131.170.980.60
Other Assets0.120.130.200.210.200.21
Total Assets120.38125.92143.89154.4293.51108.93
Short Term Debt Incl. Current Port. of LT Debt1.661.611.561.511.461.41
Accounts Payable0.810.830.940.301.341.12
Other Current Liabilities5.804.705.257.1112.2011.04
Total Current Liabilities8.277.147.758.9115.0013.57
Long Term Debt26.0626.4926.9127.3027.6728.03
Provision for Risks Charges0.000.000.000.000.000.00
Other Liabilities34.2746.9933.1325.9534.2133.27
Total Liabilities68.6080.6367.7962.1776.8874.87
Non-Equity Reserves0.000.000.000.000.000.00
Preferred Stock - Carrying Value0.000.000.000.000.000.00
Common Equity51.7745.2976.1092.2516.6334.05
Total Shareholders Equity51.7745.2976.1092.2516.6334.05
Accumulated Minority Interest0.000.000.000.000.000.00
Total Equity51.7745.2976.1092.2516.6334.05
Total Liabilities & Stockholders Equity120.38125.92143.89154.4293.51108.93
Book Value Per Share1.861.712.953.831.382.93
Tangible Book Value Per Share1.821.672.913.781.302.87
Full-Time Employees-676668-102
Price to Book Ratio5.122.671.443.021.890.90
Return on Assets-36.87-45.66-33.16-32.06-67.76-56.97
Return on Equity-115.28-135.15-70.93-62.71-205.16-143.89
Return on Invested Capital-9.75-45.49-17.9016.10-49.14-37.88
Quick Ratio10.4712.8214.0213.323.455.18
Current Ratio10.4712.8214.0213.323.455.18

Cash flow, quarterly

Currency USD, millions
Metric2026Q32026Q22026Q12025Q42025Q32025Q2
Net Income-7.59-32.65-18.4420.13-21.77-23.52
Depreciation0.580.600.640.680.670.70
Other Funds (Non Cash)-9.1515.9811.72-4.853.945.17
Funds from Operations-16.16-16.07-6.0815.96-17.16-17.65
Extraordinary Item0.000.000.000.000.000.00
Changes in Working Capital0.152.55-5.86-22.211.89-2.62
Cash from Operating Activities-16.01-13.52-11.94-6.25-15.27-20.27
Capital Expenditures-0.200.00-0.12-0.370.00-0.02
Net Assets From Acquisitions0.000.000.000.000.000.00
Sale of Fixed Assets and Businesses0.000.000.000.040.020.01
Purchase or Sale of Investments0.000.000.000.000.000.00
Purchase of Investments0.000.000.000.000.000.00
Sale Or Maturity of Investments0.000.000.000.000.000.00
Other Uses0.000.000.000.000.000.00
Other Sources0.000.000.000.000.000.00
Cash from Investing Activities-0.200.00-0.11-0.330.02-0.01
Cash Dividends Paid0.000.000.000.000.000.00
Preferred Dividends (Cash Flow)0.000.000.000.000.000.00
Change in Capital Stock10.960.000.7477.521.665.30
Repurchase of Common Pref Stock0.000.000.000.000.000.00
Sale of Common Pref Stock10.960.000.7477.521.665.30
Proceedsfrom Stock Options10.960.000.747.321.665.30
Issuance or Reduction of Debt, Net0.000.000.000.000.000.00
Change in Long Term Debt0.000.000.000.000.000.00
Issuance of Long Term Debt0.000.000.000.000.000.00
Reduction of Long Term Debt0.000.000.000.000.000.00
Net Financing Active Other Cash Flow0.000.000.000.000.000.00
Other Financing Activities Uses0.000.000.000.000.000.00
Cash from Financing Activities10.960.000.7477.521.665.30
Net Change in Cash-5.25-13.52-11.3170.94-13.59-14.98
Free Cash Flow-16.01-13.52-11.96-6.27-15.27-20.27

Revenue breakdown

United States2024: 68.70M 2025: 34.26M
Total Biological Products, (No Diagnostic Substances) revenue2024: 68.70M 2025: 34.26M

Short interest

shares short against float, oldest to newest
SettlementOf floatShares shortFloatAvg volume
2026-10-308.68%2.1M24.2M255.61K
2026-10-159.87%2.4M23.9M269.37K
2026-09-3010.54%2.5M23.9M334.77K
2026-09-159.31%2.2M23.9M394.62K
2026-08-3110.55%2.5M23.9M417.39K
2026-08-149.82%2.4M24.5M429.14K
2026-07-3111.77%2.9M24.5M423.72K
2026-07-1510.41%2.4M22.9M408.26K
2026-06-3010.02%2.3M22.9M340.85K
2026-06-158.48%1.9M22.9M312.82K
2026-05-297.31%1.7M22.9M300.41K
2026-05-156.61%1.5M22.9M267.61K
2026-04-306.15%1.4M23.0M268.72K
2026-04-155.42%1.2M23.0M273.58K
2026-03-316.06%1.2M19.3M271.11K
2026-03-137.23%1.4M19.3M235.59K
2026-02-277.36%1.4M18.8M216.74K
2026-02-137.89%1.5M18.8M227.05K
2026-01-307.26%1.4M19.0M235.58K
2026-01-156.97%1.3M19.0M240.46K

Option chain

expiry 2026-11-20
TypeStrikeBidAskLastIVOpen intVolumeDeltaThetaVega
call2.504.609.000.0029.1590.000.000.952-0.0620.001
call5.002.006.203.309.6994.000.000.895-0.0590.003
call7.500.252.502.753.0122100.000.786-0.0460.004
call10.000.001.600.653.34844.000.000.545-0.1100.006
call12.500.001.000.543.07764.000.000.386-0.0940.006
call15.000.004.900.984.1216.000.000.341-0.1220.005
call17.500.004.900.154.7163.000.000.316-0.1350.005
put2.500.004.900.007.9030.000.00-0.047-0.0620.001
put5.000.004.900.954.1559.000.00-0.102-0.0590.003
put7.500.000.400.184.78814.000.00-0.244-0.1190.005
put10.000.104.900.757.82441.000.00-0.465-0.1070.006
put12.501.003.903.402.32334.000.00-0.621-0.1050.005
put15.003.507.709.405.7221.000.00-0.659-0.1220.005
put17.506.0010.500.006.8700.000.00-0.683-0.1350.005

Latest SEC filings

30
FiledFormDescriptionPeriodLink
2026-11-10144Filing for proposed sale of securities under Rule 144.SEC
2026-11-098-KCurrent report2026-11-09SEC
2026-11-06144Filing for proposed sale of securities under Rule 144.SEC
2026-11-068-KCurrent report2026-11-05SEC
2026-11-06424B5SEC
2026-11-05144Filing for proposed sale of securities under Rule 144.SEC
2026-11-05FWPFiling under Securities Act Rule 163/433 of free writing prospectuses.SEC
2026-11-058-KCurrent report2026-11-05SEC
2026-11-038-KCurrent report2026-11-03SEC
2026-11-0310-QQuarterly report pursuant to Section 13 or 15(d)2026-09-30SEC
2026-11-03SCHEDULE 13G/ASEC
2026-10-27SCHEDULE 13GSEC
2026-09-304Statement of changes in beneficial ownership of securities2026-09-28SEC
2026-09-294Statement of changes in beneficial ownership of securities2026-09-25SEC
2026-08-24SCHEDULE 13G/ASEC
2026-08-248-KCurrent report2026-08-24SEC
2026-08-07S-8Initial registration statement for securities to be offered to employees pursuant to employee benefit plansSEC
2026-08-0610-QQuarterly report pursuant to Section 13 or 15(d)2026-06-30SEC
2026-08-068-KCurrent report2026-08-06SEC
2026-08-033Initial statement of beneficial ownership of securities2026-08-01SEC
2026-08-033Initial statement of beneficial ownership of securities2026-08-01SEC
2026-08-033Initial statement of beneficial ownership of securities2026-08-01SEC
2026-07-29SCHEDULE 13G/ASEC
2026-07-278-KCurrent report2026-07-23SEC
2026-07-20SCHEDULE 13GSEC
2026-07-018-KCurrent report2026-07-01SEC
2026-06-168-KCurrent report2026-06-10SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC
2026-06-054Statement of changes in beneficial ownership of securities2026-06-03SEC

Insider activity by month

MonthBoughtBuysSoldSells
2026-110000
2026-100000
2026-0929.50K300
2026-080000
2026-070000
2026-060000
2026-050000
2026-040000
2026-030000
2026-0200148.06K4
2026-0100283.21K4
2025-1233.71K300
2025-110034.90K3

Institutional holders

Manager% owned
Aberdeen Group plc8.08%
Bleichroeder LP7.82%
Octagon Capital Advisors LP5.23%
BOOTHBAY FUND MANAGEMENT, LLC5.22%
BlackRock, Inc.4.55%
VANGUARD CAPITAL MANAGEMENT LLC4.33%
Lynx1 Capital Management LP3.68%
DRIEHAUS CAPITAL MANAGEMENT LLC3.67%
Empery Asset Management, LP3.01%
Affinity Asset Advisors, LLC2.51%

Funds

Fund% owned
abrdn World Healthcare Fund4.43%
abrdn Life Sciences Investors4.21%
VANGUARD TOTAL STOCK MARKET INDEX FUND3.02%
iShares Russell 2000 ETF1.66%
VANGUARD EXTENDED MARKET INDEX FUND1.21%
Meridian Contrarian Fund1.06%
Fidelity Small Cap Index Fund1.01%
iShares Russell 2000 Value ETF0.65%
VANGUARD RUSSELL 2000 INDEX FUND0.50%
Fidelity Extended Market Index Fund0.47%

OakChart. DTIL. Cached 15 minutes.